Skip to content
Search

Latest Stories

GSK posts surging profit ahead of consumer health spin-off in July

British pharmaceutical giant GlaxoSmithKline (GSK) beat first-quarter sales and earnings forecasts on Wednesday (April 27), helped by demand for its Covid-19 therapy and shingles vaccine, as the company moves towards the July separation of its consumer health business.

Profit after tax jumped 68 percent to £1.8 billion ($2.3 billion, 2.1 billion euros) compared with the start of 2021.


Sales climbed 32 percent to almost £9.8 billion.

"We have delivered strong first-quarter results in this landmark year for GSK, as we separate consumer healthcare and start a new period of sustained growth," chief executive Emma Walmsley said in the earnings statement.

"Our results reflect further good momentum across speciality medicines and vaccines, including the return to strong sales growth for Shingrix and continuing pipeline progress."

The shingles vaccine generated £698 million in quarterly sales, beating analyst estimates of 528 million.

Walmsley is seeking to reshape GSK after facing fierce investor criticism over the company's delay in producing Covid jabs and treatments.

However in February, Canada approved a Covid-19 vaccine developed jointly by GSK and Canadian group Medicago.

The British company is meanwhile awaiting EU regulatory approval of its Covid-19 vaccine produced alongside French peer Sanofi.

Aside from Covid vaccines, GSK earlier this month agreed to buy US group Sierra Oncology for $1.9 billion.

GSK is also in the process of demerging its consumer healthcare arm Haleon -- a joint venture with US peer Pfizer -- to concentrate on its main pharmaceutical business.

After rejecting a bid worth £50 billion for the unit from consumer goods titan Unilever, GSK plans to list the newly-named Haleon on the London stock market.

GSK continues "to see very good momentum in consumer healthcare, demonstrating strong potential of this business ahead of its proposed demerger in July, to become Haleon", Walmsley added on Wednesday.

The consumer unit's products include Sensodyne toothpaste, pain relief drug Panadol and cold treatment Theraflu.

More For You

Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less